S

SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600

Watchlist Manager
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
Watchlist
Price: 18.72 HKD Market Closed
Market Cap: 11.8B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
SciClone Pharmaceuticals (Holdings) Ltd

There are no price targets for SciClone Pharmaceuticals (Holdings) Ltd.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
SciClone Pharmaceuticals (Holdings) Ltd Competitors:
Price Targets
2161
Jbm (Healthcare) Ltd
9% Upside
4536
Santen Pharmaceutical Co Ltd
29% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
1% Upside
Z
300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
8% Upside
2161
Jbm (Healthcare) Ltd
9% Upside
4536
Santen Pharmaceutical Co Ltd
29% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
1% Upside
Z
300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
8% Upside
N
603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
53% Upside
VENUSREM
Venus Remedies Ltd
23% Downside

Revenue
Forecast

Revenue Estimate
SciClone Pharmaceuticals (Holdings) Ltd

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's revenue is 18%. The projected CAGR for the next 2 years is 16%.

18%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
SciClone Pharmaceuticals (Holdings) Ltd

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's operating income is 19%. The projected CAGR for the next 2 years is 7%.

19%
Past Growth
7%
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
SciClone Pharmaceuticals (Holdings) Ltd

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's net income is 16%. The projected CAGR for the next 2 years is 9%.

16%
Past Growth
9%
Estimated Growth
Estimates Accuracy
8%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SciClone Pharmaceuticals (Holdings) Ltd's stock price target?
Not Available

SciClone Pharmaceuticals (Holdings) Ltd doesn't have any price targets made by Wall Street professionals.

What is SciClone Pharmaceuticals (Holdings) Ltd's Revenue forecast?
Projected CAGR
16%

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's revenue is 18%. The projected CAGR for the next 2 years is 16%.

What is SciClone Pharmaceuticals (Holdings) Ltd's Operating Income forecast?
Projected CAGR
7%

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's operating income is 19%. The projected CAGR for the next 2 years is 7%.

What is SciClone Pharmaceuticals (Holdings) Ltd's Net Income forecast?
Projected CAGR
9%

For the last 5 years the compound annual growth rate for SciClone Pharmaceuticals (Holdings) Ltd's net income is 16%. The projected CAGR for the next 2 years is 9%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.